Myogen
Advancing cardiovascular health with innovative small molecule therapeutics for unmet medical needs.
Advancing cardiovascular health with innovative small molecule therapeutics for unmet medical needs.
Myogen is a biopharmaceutical company founded in 1996, dedicated to advancing cardiovascular health with innovative small molecule therapeutics. Their slogan "Advancing cardiovascular health with innovative small molecule therapeutics for unmet medical needs" reflects their mission. The company focuses on the discovery, development, and commercialization of small molecule therapeutics targeting cardiovascular disorders. With a strong emphasis on their advanced understanding of cardiovascular disease biology and clinical expertise in cardiovascular therapeutics, Myogen aims to address serious and debilitating cardiovascular disorders inadequately treated by existing therapies. The company's last investment was a $40.00M Series D investment on 29 August 2003, with participation from notable investors including New Enterprise Associates, Greenspring Associates, InterWest Partners, Sequel Venture Partners, JPMorgan Partners, CMEA Ventures, Pacific Rim Partners, and Perseus-Soros Biopharmaceutical Fund.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series D | $40.00M | 8 |
|
29 Aug 2003 |
| Series D | $14.00M | 2 |
|
03 Jan 2002 |
| Series D | $52.40M | - | 28 Aug 2001 | |
| Series D | $63.37M | - | 01 Jun 2001 | |
| Venture Round | $18.00M | - | 15 Dec 1999 |
No recent news or press coverage available for Myogen.
We care about your data, and we'd love to use cookies make your experience better.
